Ocular Therapeutix has spent years chasing a wet AMD treatment that could stretch the time between injections from months to something closer to a year. The company believes it now has the data and the FDA’s blessing to move forward. Today’s Investor Day in Bedford, Massachusetts is the public unveiling of that plan.
The core of the announcement is straightforward: the company will submit its New Drug Application for AXPAXLI in the fourth quarter of 2026. That filing will combine efficacy and safety data from the SOL-1 trial with interim safety data from the ongoing SOL-R study.
The FDA has signed off on this approach. That alignment is the headline. But the strategy runs deeper.
Ocular Therapeutix is using the 505(b)(2) regulatory pathway, which allows them to rely on some existing safety data from other approved drugs. This can shave up to 60 days off the FDA review clock.
The company is not hiding its urgency. They want this drug reviewed as fast as the rules allow. The SOL-R trial itself has been redesigned.
A new secondary endpoint now tests whether AXPAXLI is superior to aflibercept at Week 96. That is a direct challenge to the current standard of care. If the data holds, the label could carry a superiority claim.
That would matter enormously in a market where every competitor claims convenience, but few can claim better outcomes at two years. SOL-R will stay masked until that 96-week data is ready.
Topline results are not expected until the first quarter of 2028. That means the NDA submission in late 2026 will not include the superiority data. The initial approval, if it comes, will rest on the shorter-term evidence from SOL-1 and the interim safety read from SOL-R.
The superiority claim would come later, as a label expansion. The company is also streamlining its diabetic retinopathy program.
After strong SOL-1 results, they are prioritizing the HELIOS-3 trial as a potential single registrational study. That trial is testing a 12-month dosing interval for AXPAXLI. If that works, the drug’s utility expands beyond wet AMD into a second major retinal disease.
The wet AMD market is crowded. Regeneron’s Eylea and Roche’s Vabysmo dominate. Both require injections every one to four months.
Aflibercept, the drug AXPAXLI is now being tested against head-to-head at 96 weeks, is the established benchmark. Ocular Therapeutix is betting that a longer-lasting therapy — one that could mean two injections a year instead of six or eight — will shift prescribing patterns.
The FDA’s willingness to accept this combined data package suggests the agency sees the logic. Wet AMD patients often struggle with the burden of frequent injections. Missed appointments lead to vision loss.
A drug that works longer is not just a convenience; it is a compliance tool. None of this is guaranteed.
The SOL-R data is still blinded. The 96-week superiority endpoint is ambitious. The 505(b)(2) pathway may accelerate review, but it does not guarantee approval.
The company is betting big on a single drug, and the timeline stretches years out. Today’s event is the sales pitch. The real test comes in the data releases and the FDA’s final decision.
But for now, Ocular Therapeutix has a plan, a regulator on board, and a clear path to filing. That is more than most biotech companies can say.
